ReShape Lifesciences Files S-1
Ticker: HIND · Form: S-1 · Filed: Dec 20, 2024 · CIK: 1427570
| Field | Detail |
|---|---|
| Company | Reshape Lifesciences Inc. (HIND) |
| Form Type | S-1 |
| Filed Date | Dec 20, 2024 |
| Risk Level | medium |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $833.333, $5.22, $5,000,000, $4.50, $1.15 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: S-1, registration-statement, lifesciences
TL;DR
ReShape Lifesciences dropped an S-1 filing on 12/20/24 - check it for the latest on their financials.
AI Summary
ReShape Lifesciences Inc. filed an S-1 form on December 20, 2024, detailing its financial status and business operations. The company, formerly Obalon Therapeutics Inc., is based in San Clemente, California, and operates in the Pharmaceutical Preparations sector. The filing provides information on its fiscal year ending December 31 and includes details related to warrants and financial modeling inputs as of December 31, 2023.
Why It Matters
This S-1 filing provides crucial insights into ReShape Lifesciences' financial health and strategic direction, impacting investors and the healthcare industry.
Risk Assessment
Risk Level: medium — S-1 filings often indicate a company is seeking to raise capital or undergo significant corporate changes, which inherently carry risks.
Key Numbers
- 333-283952 — SEC File Number (Identifies the specific SEC filing for ReShape Lifesciences Inc.)
- 241565045 — Film Number (Internal SEC processing number for the filing.)
Key Players & Entities
- ReShape Lifesciences Inc. (company) — Filer of the S-1 document
- Obalon Therapeutics Inc. (company) — Former name of ReShape Lifesciences Inc.
- 20241220 (date) — Filing date of the S-1
- 2023-12-31 (date) — Fiscal year end date and date for financial inputs
- 1001 CALLE AMANECER, SAN CLEMENTE, CA 92673 (address) — Business and mailing address of ReShape Lifesciences Inc.
FAQ
What is the primary purpose of this S-1 filing for ReShape Lifesciences Inc.?
The S-1 filing is a registration statement filed with the SEC, typically used when a company plans to offer its securities to the public, indicating potential capital raising or significant corporate actions.
When was the S-1 filing submitted by ReShape Lifesciences Inc.?
The S-1 filing was submitted on December 20, 2024.
What was ReShape Lifesciences Inc. formerly known as?
ReShape Lifesciences Inc. was formerly known as Obalon Therapeutics Inc., with a name change date of February 20, 2008.
What is the business address of ReShape Lifesciences Inc.?
The business address is 1001 CALLE AMANECER, SAN CLEMENTE, CA 92673.
What financial inputs were used in the Black-Scholes model as of December 31, 2023, according to the filing?
As of December 31, 2023, the filing references inputs for the Black-Scholes model including Share Price, Risk-Free Interest Rate, Price Volatility, and Expected Term, associated with Representative SWarrantsOctober2023.
Filing Stats: 4,607 words · 18 min read · ~15 pages · Grade level 14.6 · Accepted 2024-12-20 06:27:55
Key Financial Figures
- $833.333 — ote in the original principal amount of $833.333.34 that we issued to Ascent on October
- $5.22 — 2024 at an initial conversion price of $5.22 per share (the "Convertible Note") and
- $5,000,000 — we may receive gross proceeds of up to $5,000,000 from the sale of common stock to Ascent
- $4.50 — orted on the Nasdaq Capital Market, was $4.50 per share. Investing in shares of our
- $1.15 million — development has received approximately $1.15 million dollars of nondilutive NIH grant suppor
- $5.16 million — ur liabilities, for a purchase price of $5.16 million in cash, subject to adjustment based on
Filing Documents
- rsls-20231231xs1.htm (S-1) — 2963KB
- rsls-20231231xex4d31.htm (EX-4.31) — 104KB
- rsls-20231231xex5d1.htm (EX-5.1) — 14KB
- rsls-20231231xex10d26.htm (EX-10.26) — 329KB
- rsls-20231231xex23d2.htm (EX-23.2) — 3KB
- rsls-20231231xexfees.htm (EX-FILING FEES) — 21KB
- rsls-20231231xs1007.jpg (GRAPHIC) — 12KB
- rsls-20231231xs1009.jpg (GRAPHIC) — 67KB
- rsls-20231231xex5d1004.jpg (GRAPHIC) — 6KB
- rsls-20231231xex5d1005.jpg (GRAPHIC) — 1KB
- rsls-20231231xex5d1006.jpg (GRAPHIC) — 1KB
- rsls-20231231xex5d1003.jpg (GRAPHIC) — 15KB
- 0001104659-24-130324.txt ( ) — 10915KB
- rsls-20231231.xsd (EX-101.SCH) — 59KB
- rsls-20231231_cal.xml (EX-101.CAL) — 62KB
- rsls-20231231_def.xml (EX-101.DEF) — 292KB
- rsls-20231231_lab.xml (EX-101.LAB) — 527KB
- rsls-20231231_pre.xml (EX-101.PRE) — 440KB
- rsls-20231231xs1_htm.xml (XML) — 1653KB
RISK FACTORS
RISK FACTORS 11 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 46 CAPITALIZATION 47
USE OF PROCEEDS
USE OF PROCEEDS 48 MARKET AND DIVIDEND INFORMATION FOR OUR COMMON STOCK 49 DESCRIPTION OF EQUITY FINANCING TRANSACTION 50 DESCRIPTION OF CONVERTIBLE NOTE TRANSACTION 52 THE SELLING STOCKHOLDER 53
DESCRIPTION OF CAPITAL STOCK
DESCRIPTION OF CAPITAL STOCK 54 SECURITIES ACT RESTRICTIONS ON RESALE OF OUR SECURITIES 58 PLAN OF DISTRIBUTION 59 RESHAPE AND VYOME UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS 61 LEGAL MATTERS 72 EXPERTS 72 INCORPORATION OF CERTAIN INFORMATION BY REFERENCE 72 WHERE YOU CAN FIND MORE INFORMATION 73 DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITY 73 i Table of Contents ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S-1 under which the selling stockholder may, from time to time, sell the securities offered by them described in this prospectus. We will not receive any proceeds from the sale by the selling stockholder of the securities offered by them described in this prospectus. You should not assume that the information contained in this prospectus is accurate on any date subsequent to the date set forth on the front cover of this prospectus, even though this prospectus is delivered or our securities registered under the registration statement of which this prospectus forms a part are sold or otherwise disposed of on a later date. It is important for you to read and consider all information contained in this prospectus in making your investment decision. You should also read and consider the information in the documents to which we have referred you under the captions " Where You Can Find Additional Information " in this prospectus. Neither we nor the selling stockholder have authorized anyone to provide any information or to make any representation other than those contained in this prospectus. You must not rely upon any information or representation not contained in this prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This prospectus does not constitute an offer to sell or the solicitation of an offer to buy any of our securities other than the securities covered hereby, nor does this prospe